SAB Biotherapeutics, Inc. (SABS)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $3.20
- As of
Kresmion compiles this page from SABS's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
SAB Biotherapeutics, Inc. (SABS): 3 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-13.
See the full SABS dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for SABS on one page. Preview it with sample data, then open it live with a free account.
Preview the SABS dossierActive events for SABS
- high13F: large increase
CITADEL ADVISORS LLC added +256% to SABS (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +359% to SABS (2026Q2)
- mediumEarnings above estimates
Q2-2026: Beat consensus by 5.1%, EPS $-0.28 vs $-0.2952 estimate
- mediumEarnings below estimates
Q2-2025: Missed consensus by 34.3% - EPS $-1.09 vs $-0.8119 estimate
- mediumEarnings above estimates
Q3-2025: Beat consensus by 70.9% - EPS $-0.15 vs $-0.5161 estimate
FREE, NO ACCOUNT
Every event on SABS, as it fires
You are seeing 5 of 7 events recorded on SABS since 2026-06-07.
The five above landed across 3 days. The other 2 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in SABS (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 78397T202 · 2026Q2 | $10.7M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 78397T202 · 2026Q2 | $837K | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 78397T202 · 2026Q2 | $245K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, SABS
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
SABS against its peers
SABS's return on equity of 8.8% ranks in the 87th percentile of 18 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | SABS | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 0.0 USD | 14.2M USD | 8 | 17 |
| Operating margin | n/a | -306.1% | n/a | 16 |
| Net margin | n/a | -325.5% | n/a | 16 |
| Return on equity | 8.8% | -66.6% | 87 | 18 |
Peers (22): NWBO, IPSC, LCTX, FATE, ABEO, QTTB, RCKT, OCGN, CABA, BCYC, LRMR, VNDA, IMRX, ACIU, ARCT, GLSI, AGEN, ANIK, PALI, IRD, PRLD, PROK. Left out: VCRE (no annual filing), CUVL (no annual filing), VOGX (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (SABS: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow SABS on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to SABS for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.